Original article by Tim Binsted
The Australian Financial Review – Page: 15 : 8-Sep-15
Shares in Australian biotechnology group Starpharma closed 21.3 per cent higher at $A0.74 on 7 September, after securing a licensing agreement with AstraZeneca for the use of its dendrimer drug delivery technology. Starpharma CEO Jackie Fairley say the deal could potentially be worth at least $US450m to the company. Starpharma recently posted a 2014-15 loss of $A18.95m.
STARPHARMA HOLDINGS LIMITED – ASX SPL, ASTRAZENECA PLC, McGRATH REAL ESTATE PTY LTD, ALLAN GRAY AUSTRALIA PTY LTD, FIDELITY INVESTMENTS AUSTRALIA LIMITED